Evidence map›Paper›PMID 39252827›Full record

ArticleMolecular & cellular oncology2024

An antibody-drug conjugate for endometrioid carcinoma based on the expression of cell adhesion molecule 1.

Man Hagiyama, Azusa Yoneshige, Tomoyuki Otani, Akihiro Wada, Fuka Takeuchi, Yuji Shoya, Takao Inoue, Akihiko Ito

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular & cellular oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Man HagiyamaDepartment of Pathology, Kindai University Faculty of Medicine, Osaka-sayama, Osaka, Japan.
Azusa YoneshigeDepartment of Pathology, Kindai University Faculty of Medicine, Osaka-sayama, Osaka, Japan.
Tomoyuki OtaniDepartment of Pathology, Kindai University Faculty of Medicine, Osaka-sayama, Osaka, Japan.
Akihiro WadaDepartment of Pathology, Kindai University Faculty of Medicine, Osaka-sayama, Osaka, Japan.
Fuka TakeuchiDivision of Molecular Pathology, Graduate School of Medicine, Kindai University, Osaka-sayama, Osaka, Japan.
Yuji ShoyaDivision of Molecular Pathology, Graduate School of Medicine, Kindai University, Osaka-sayama, Osaka, Japan.
Takao InoueDepartment of Pathology, Kindai University Faculty of Medicine, Osaka-sayama, Osaka, Japan.
Akihiko ItoDepartment of Pathology, Kindai University Faculty of Medicine, Osaka-sayama, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell adhesion molecule 1 (CADM1), an immunoglobulin superfamily member, is expressed in endometrial glandular cells highly during the proliferative phase but lowly during the secretory phase. Previously, a CADM1-targeting antibody-drug conjugate (ADC) was generated, in which a humanized anti-CADM1 ectodomain antibody h3E1 was linked with monomethyl auristatin E (h3E1-MMAE ADC). The present study aimed at probing whether this ADC could be useful for the treatment of endometrial neoplasm. Firstly, immunohistochemistry for CADM1 was conducted on proliferative-phase endometrium (

Indexed as

CADM1early-stage cancerendometrial hyperplasiafertility preservationgynecologic oncology

Identifiers

PMID39252827
PMCPMC11382700

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.